2015 American Transplant Congress
Prospective, 6 Month, Open Label, Conversion Study from Mycophenolate Mofetyl to Mycophenolic Acid Evaluating the Severity of Gastro-Intestinal Symptoms and Mycophenolic Acid Urinary Metabolite as a Surrogate Marker of Plasmatic Area Under the Curve
Introduction: Treatment with mycophenolate mofetil (MMF) often results in adverse gastro-intestinal (GI) events, which can lead to dose reductions that in turn can increase the…2015 American Transplant Congress
Assessment of Bleeding and Thrombosis in Responders and Initial Non-Responders to Aspirin After Continuous-Flow Left Ventricular Assist Device Placement
Medical University of South Carolina, Charleston, SC.
Purpose: This study evaluates bleeding and thrombosis following left ventricular assist device (LVAD) placement using platelet inhibition monitoring to determine responders to standard aspirin dosing…2015 American Transplant Congress
Phenotypic Personalized Medicine: Mechanism-Independent Convergence Into Target Serum Tacrolimus Levels for Optimized Liver Transplant Immunosuppression
PURPOSE:Immunosuppressive drugs such as tacrolimus have narrow therapeutic ranges and their dosing variability necessitates intensive drug monitoring. This study aimed to use Feedback System Control…2015 American Transplant Congress
Safety and Efficacy of Low Dose and Very Low Dose Extended-Release Tacrolimus / MMF in De Novo Kidney Transplant Recipients
Recently, once-daily tacrolimus extended-release formulation (TACER) has been accepted in kidney transplantation, however its optimal dosing are not well evaluated. We have validated low dose…
- « Previous Page
- 1
- …
- 7
- 8
- 9